ArticleNeuropsychiatric disease and treatment2025
Cenobamate for Difficult-to-Treat Epilepsy - Selected Case Vignettes.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cannabidiol Use in Developmental and Epileptic Encephalopathies: A Syndrome- and Age-Stratified Systematic Review and Meta-analysis.CNS drugs · 2026Pooled it
- Beyond efficacy: defining the cenobamate response profile.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Epilepsy affects millions worldwide, presenting unique challenges in specific populations such as the elderly, children, and patients with comorbidities or drug-resistant forms. Tailored approaches addressing unmet needs in these subgroups are critical to improving outcomes. Areas Covered: This research uniquely integrates real-world evidence and detailed case vignettes from the EPI CONNECT project to evaluate the role of cenobamate in managing these complex cases, providing practical insights beyond traditional clinical trials. The article explores the potential of cenobamate, a novel antiseizure medication with dual mechanisms of action, in improving seizure control, simplifying polytherapy, and enhancing tolerability across various subpopulations. Case-based narratives illustrate its practical use in challenging scenarios. Expert Opinion: Cenobamate offers important advantages for underserved epilepsy populations, including seizure improvement, polypharmacy reduction, and improved adherence and quality of life. This review seeks to bridge current clinical practice with ongoing research efforts, fostering improved personalized treatment approaches and advancing understanding of cenobamate's long-term role in managing difficult-to-treat epilepsy populations. It aims to provide practical guidance for clinicians and to highlight future research directions, encouraging ongoing investigation into long-term efficacy, safety, and personalized care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.